Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Praxis Precision Medicines Inc. (PRAX)

NASDAQ: PRAX · Pharmaceutical Preparations · Boston, MA

Our rating: Cautious

Cautious reaffirmed at $337.59, moderate conviction, November 10, 2026.

Breaks if: The Cautious call would be wrong if, within six months of 10 November 2026, Praxis discloses a pivotal-trial primary endpoint hit with clear statistical significance and the stock holds above $420 for at least five consecutive sessions — indicating the market has concluded the core pipeline is intact and the 9 November event was a contained setback rather than a thesis-breaker. A sustained move through that level on a clinical catalyst would signal the valuation has found new fundamental footing.

Key figures

Market value$8.4B
Revenue, last 12 monthsn/a
Net income, last 12 months−$359M
Free cash flow, last 12 months−$324M
Price to earningsn/a
Free cash flow yield−3.9%
Dividend yield0.0%
Operating marginn/a
Return on equity−44.8%
Beta to the S&P 5001.01
Volatility, annualized138.5%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-3.23−$83M
June 30, 2026n/an/a$-2.87−$78M
March 31, 2026n/an/a$-3.20−$86M
December 31, 2025$0.00−100.0%$-3.51−$76M
September 30, 2025$0.00−100.0%$-3.36−$65M
June 30, 2025$0.00−100.0%$-3.31−$55M
March 31, 2025$0.00−100.0%$-3.29−$53M
December 31, 2024$7M1349.1%$-3.00−$56M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

20 ledger entries and 17 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.